Source: http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Pages/reqNonUSLab.aspx
Timestamp: 2016-02-14 03:49:48
Document Index: 611811769

Matched Legal Cases: ['art 58', 'art 493', 'art 56', 'arts 50', 'art 11', 'art 11']

Clinical Trials Requirements for Non-US Labs You may be trying to access this site from a secured browser on the server. Please enable scripts and reload this page.
Main Content AreaDivision of AIDS (DAIDS) Requirements for Non-U.S. Laboratories
Guidance to Investigators Participating in DAIDS-Supported and/or -Sponsored Clinical Trials
This document outlines DAIDS laboratory-related requirements and deliverables for non-U.S. laboratories.
Laboratories should conduct operations in accordance with Good Clinic​al Laboratory Practices (GCLP). GCLP embraces the research, pre-clinical and clinical aspects of Good Laboratory Practices (GLP). Complying with GCLP is an ongoing process that is central to optimal clinical research laboratory operations. DAIDS and/or DAIDS contractors may monitor the progress toward GCLP compliance through audits and/or site visits. GCLP compliance will ensure that consistent, reproducible, auditable, and reliable laboratory results that support clinical trials will be produced in an environment conducive to study reconstruction, as well as ensure the safety of the research subjects and those who perform the laboratory testing.
The DAIDS guidelines for GCLP standards (PDF) document is provided to define the standards that encompass GCLP which include applicable portions of 21 Code of Federal Regulations (CFR) part 58, or GLP, and 42 CFR part 493, or Clinical Laboratory Improvement Amendment (CLIA) rules. Due to the ambiguity of some parts of these regulations, these DAIDS GCLP standards also include guidance from accrediting bodies such as the College of American Pathologists (CAP) and South African National Accreditation System.
These GCLP standards should be applied to all laboratories performing testing for clinical trials supported and/or sponsored by the DAIDS. Institutions must also meet sponsor-specific requirements as outlined in the Sponsor Statement section of the GCLP standards document.
Accreditation by CAP or an equivalent in-country accrediting body that meets ISO 15189:2007 Standards is recommended.
Laboratory Safety, Diagnosis and Food and Drug Administration (FDA)-approved Primary Endpoints Tests
Tests that are used for diagnosis (e.g., HIV, TB, Syphilis, HSV), determining eligibility (e.g., pregnancy test), monitoring the safety of the intervention (e.g. hematology, chemistry), making patient management decisions (e.g., CD4, viral load), or as primary study endpoints should be performed in laboratories that conduct operations in accordance with GCLP.
These tests (including CLIA waived tests) should be quality assured by DAIDS-approved external quality assurance (EQA) providers, such as the CAP or equivalent provider. When not available, alternative proficiency assessments should be devised and proposed to DAIDS for approval. DAIDS will verify participation and successful performance of the laboratory in the various EQA programs.
CD4 determinations should be done using standard flow cytometric measurements or protocol-mandated technology. Consideration should be given to the Centers for Disease Control and Prevention (CDC) guidelines that describe dual-platform technology – Morbidity and Mortality Weekly Report (MMWR) 1997;46 (No. RR-2), or single- platform technology - MMWR 2003; 52(RR-02).
The CD4 laboratory should successfully participate in the CD4 proficiency testing program administered by the United Kingdom National External Quality Assessment Service (UKNEQAS) and must be responsive to the trouble-shooting and assistance efforts by the DAIDS Immunology Quality Assessment (IQA) contract. (See Information about the UKNEQAS CD4 PT program). The CD4 laboratory will have to pass at least one round of proficiency testing (PT) before testing study subjects. Particular DAIDS-supported and/or -sponsored networks may have more stringent requirements. Enrollment in this program will have to be requested from DAIDS. The cost of participation may be borne by DAIDS or by the laboratory. There is no fee for receiving assistance from the DAIDS IQA. Laboratories are responsible for the cost of test kits/reagents used to test the proficiency panels and these too should be taken into account when preparing the budget for conducting the trial.
To request enrollment in the CD4 PT program, please email Daniella Livnat to discuss.
The use of FDA-approved methods is strongly encouraged. Laboratories performing HIV viral load tests, HIV DNA PCR and HIV genotypic drug resistance testing should participate in the DAIDS Virology Quality Assessment (VQA) program.
To request enrollment in VQA PT program(s), please email Joe Fitzgibbon. The process of achieving certification takes at least 5 months.
For laboratories performing testing for NIAID DAIDS supported and/or sponsored clinical trials, there is no fee for participating in the VQA program. However, laboratories are responsible for the cost of shipping the panels from the VQA to the laboratory, and for test kits/reagents used to test the proficiency panels. These costs should be taken into account when preparing the budget for conducting the trial.
1.3. Other tests
Different providers of EQA surveys send samples at different frequencies (e.g. most CAP surveys are sent three times a year). The laboratory should successfully pass at least one round of EQA for each clinical trial analyte and satisfy all other Network/ non-Network specific requirements before starting the trial. EQA results from safety, eligibility, and diagnostic tests will be reviewed by the DAIDS contractors and/or Network/ non-Network lab managers. The laboratory will also receive assistance and instructions for corrective actions from DAIDS contractors and/or Network/ non-Network lab managers.
The cost of participation in EQA programs (buying, shipping and testing PT panels) may be borne by DAIDS or may have to be included in the grant application. Please email Daniella Livnat to discuss.
This section covers all research tests not approved by FDA nor validated by International Conference on Harmonisation (ICH) or US Pharmacopeia. Generally, the endpoint tests should be performed in laboratories that conduct operations in accordance with GCLP.
Endpoint tests, such as new non-FDA-approved pharmacological and virological assays do not require an investigational device exemption (IDE) submission to the FDA. These are classified as investigational use only (IUO) tests while clinical studies are being done to evaluate their performance. Results from these tests are not intended to be used for the diagnosis, treatment or management of patients without confirmation by other medically established procedures. There is no existing DAIDS-supported Proficiency Testing Program for these tests, therefore, a suitable form of alternative proficiency assessments should be devised and proposed to DAIDS for approval. IRB review (21 CFR part 56) and human subjects regulations (21 CFR parts 50) apply.
RUO assays, such as Enzyme-Linked Immunosorbent Spot (ELISPOT) and Intracellular Cytokine Staining (ICS), are intended to be used for performing product advancement or basic scientific research, are not considered to be effective diagnostic tools and must be appropriately labeled “for Research Use Only, Not for use in diagnostic procedures”. External quality assurance should be applied to such tests. DAIDS has established an external quality assurance (EQA) program, EQAPOL, for laboratories performing immunogenicity assays as part of NIAID (DAIDS)-supported and/or sponsored clinical trials. Please email Jim Lane for more information on EQAPOL.
If existing EQA surveys are not available, a suitable form of alternative proficiency assessments should be devised and proposed to DAIDS for approval. Results from these assays are not to be used for making clinical decisions. See Information on EQA programs provided for RUO assays.
Study-specific Specimen Management Plan
Procedures for the management of trial specimens must be documented and followed to ensure the integrity of specimens and their timely testing. Each study should have a specimen management plan that describes study specific sample acquisition, recording, testing, storing and shipping; including specimen flow chart, quality assurance (QA) oversight and corrective action (the latter two may be included in the Laboratory Quality Management Plan). Details may be included in study/Network Manual of Operations and/or in study protocol appendices. Please refer to the SOP Checklist-Study Specific Management Plan (Word) for an example and guidance on required elements.
Study-Specific Laboratory Data Management Plan
If the laboratory plans to use a Laboratory Information Management System (LIMS) or a laboratory data management system, computerized laboratory systems should be validated and compliant with 21 CFR Part 11 for Investigational New Drug (IND) enabling studies. For non-IND studies, computerized laboratory systems should be validated and the elements of 21 CFR Part 11 should be taken into consideration.
The lab QMP describes the laboratory’s approach to management of quality and study-participant safety by providing guidance for the operation of a laboratory. It must describe procedures for monitoring, assessment and correction of problems identified in pre-analytical, analytical and post analytical aspects of all lab operations.
All laboratories performing testing that supports a clinical trial supported and/or sponsored by NIAID (DAIDS) must have a documented QMP that describes the overall quality management program of the laboratory.
The QMP should describe the following: the laboratory’s plan to ensure overall quality and patient safety, corrective action and preventive action (CAPA) activities, risk assessment activities, QC and EQA activities, monitoring of key indicators and continuous improvement plans. For additional information please refer to guidance in preparing and implementing a QMP (PDF). For information on required elements that must be included in the QMP please refer to the Lab Quality Management Checklist (MS Word) as an example.
Online Training: The GCLP eLearning modules (self-guided training) are available on the DAIDS Learning Management System (LMS) and can be completed at any time from any internet-accessible location. The DAIDS LMS is a Web-based software that offers sites the capability to assign, track, and monitor the completion of required training; thereby, increasing the efficiency and effectiveness of training management, administration, and coordination across NIAID (DAIDS)-supported and/or -sponsored clinical research sites. Information on GCLP eLearning modules.
Face to face training: The cost of the workshop is free, however all attendees are responsible for their own travel, hotel, and per diem expenses through their network or group affiliations. Training materials for each participant will be provided. Information on upcoming DAIDS-sponsored, face to face GCLP training workshops.
A certificate of participation is provided to participants that attend the full training, whether online or face to face.
DAIDS and/or its contractor may conduct laboratory-specific audit visits to determine GCLP compliance. GCLP compliance will ensure that consistent, reproducible, auditable, and reliable laboratory results that support clinical trials will be produced in an environment conducive to study reconstruction.
After an audit, performed by DAIDS and/or its contractor, an audit report will be distributed to the laboratory. The laboratory is responsible for working with DAIDS or its contractor, and the Network/non-Network, to resolve the audit report findings. These audit report findings must be adequately addressed by the laboratory to maintain a satisfactory performance standard.
For the types of audits performed and the report resolution process please refer to the GCLP Lab Audit Information Document (PDF).
Instrument and Method Validation
DAIDS requires laboratories to perform validation prior to placing a new method or instrument into routine use, whenever the conditions change for which the method has been validated or if the change is outside the original scope of the method. To minimize validation requirements, the use of FDA-approved methodologies is strongly encouraged. If non-approved methods are considered, these should be validated in a study that compares a proposed method to a FDA-approved method. DAIDS and/or contractors can provide assistance in designing and reviewing validation studies.
For information on guidelines for conducting a validation study refer to the GCLP standards/guidelines document (PDF).